Amedisys (NASDAQ:AMED) Earns “Equal Weight” Rating from Stephens

Amedisys (NASDAQ:AMED)‘s stock had its “equal weight” rating reiterated by stock analysts at Stephens in a research report issued to clients and investors on Wednesday,Benzinga reports. They presently have a $101.00 target price on the health services provider’s stock. Stephens’ target price would suggest a potential upside of 8.86% from the company’s previous close.

Amedisys Price Performance

AMED opened at $92.78 on Wednesday. The stock’s 50 day simple moving average is $89.98 and its 200 day simple moving average is $93.68. The company has a debt-to-equity ratio of 0.05, a current ratio of 1.19 and a quick ratio of 1.19. Amedisys has a 1 year low of $82.15 and a 1 year high of $98.95. The firm has a market cap of $3.04 billion, a price-to-earnings ratio of 36.82, a PEG ratio of 1.82 and a beta of 0.73.

Hedge Funds Weigh In On Amedisys

Institutional investors and hedge funds have recently bought and sold shares of the stock. National Bank of Canada FI grew its position in Amedisys by 119.0% during the 3rd quarter. National Bank of Canada FI now owns 55,592 shares of the health services provider’s stock worth $5,365,000 after acquiring an additional 30,213 shares during the last quarter. Geode Capital Management LLC grew its position in shares of Amedisys by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 567,105 shares of the health services provider’s stock worth $54,746,000 after buying an additional 7,071 shares during the last quarter. Quarry LP bought a new stake in shares of Amedisys in the 3rd quarter worth approximately $2,569,000. Charles Schwab Investment Management Inc. grew its position in shares of Amedisys by 2.7% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 346,082 shares of the health services provider’s stock worth $33,400,000 after buying an additional 9,004 shares during the last quarter. Finally, Holocene Advisors LP grew its position in shares of Amedisys by 391.4% in the 3rd quarter. Holocene Advisors LP now owns 79,036 shares of the health services provider’s stock worth $7,628,000 after buying an additional 62,953 shares during the last quarter. 94.36% of the stock is currently owned by institutional investors.

About Amedisys

Amedisys, Inc, together with its subsidiaries, provides healthcare services in the United States. It operates through three segments: Home Health, Hospice, and High Acuity Care. The Home Health segment offers a range of services in the homes of individuals for the recovery of patients from surgery, chronic disability, or terminal illness, as well as prevents avoidable hospital readmissions through its skilled nurses; nursing services, rehabilitation therapists specialized in physical, speech, and occupational therapy; and social workers and aides for assisting its patients.